Cellectis Announces Poster Presentation on BALLI-01 at

BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 -- Cellectis , a clinical-stage biotechnology company... | May 11, 2023

Related Keywords

Raleigh , North Carolina , United States , New York , Paris , France General , France , Germany , Mark Frattini , Ashleyr Robinson , Nicolas Boissel , Pascalyne Wilson , Arthur Stril , Youtube , Nasdaq , Cellectis The Company Euronext Growth , Securities Exchange Commission , Linkedin , European Hematology Association , Euronext Growth , Hybrid Congress , Chief Medical Officer , Updated Results , B Cell Acute Lymphoblastic Leukemia , Lassistance Publique , Nasdaq Global Market , Private Securities Litigation Reform Act , Annual Report , Chief Business Officer , Lifesci Advisors , Cellectis Sa Stock Exchange , News , Information , Press Release , Abstract , Emonstrates , Safety , End , Reliminary , Efficacy , F , Cart22 , N , Heavily , Pretreated , Opulationnew , Bay , 023 , Cellectis , Iotechnology Alcls Fr0010425595 ,